PhosTAC7

CAS No. 3016307-75-5

PhosTAC7( —— )

Catalog No. M37132 CAS No. 3016307-75-5

PhosTAC7 successfully induced ternary protein complex formation and dephosphorylation of phosphatidylserine 318 (pS318) by Halo-FOXO3a in a dose-dependent manner.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 439 Get Quote
5MG 655 Get Quote
10MG 1121 Get Quote
25MG 2134 Get Quote
50MG 3432 Get Quote
100MG 4437 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PhosTAC7
  • Note
    Research use only, not for human use.
  • Brief Description
    PhosTAC7 successfully induced ternary protein complex formation and dephosphorylation of phosphatidylserine 318 (pS318) by Halo-FOXO3a in a dose-dependent manner.
  • Description
    PhosTAC7 successfully induced ternary protein complex formation and dephosphorylation of phosphatidylserine 318 (pS318) by Halo-FOXO3a in a dose-dependent manner.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3016307-75-5
  • Formula Weight
    1119.77
  • Molecular Formula
    C58H87ClN2O17
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](C(=O)N1[C@H](C(O[C@H](CCC2=CC(OC)=C(OC)C=C2)C3=CC(OCC(NCCOCCOCCOCCOCCOCCOCCOCCCCCCCl)=O)=CC=C3)=O)CCCC1)(CC)C4=CC(OC)=C(OC)C(OC)=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 3-Phosphoglyceric ac...

    3-Phosphoglyceric acid is a metabolic intermediate in glycolysis and the Calvin cycle, and it is also involved in alveolar macrophage epigenetic regulation.

  • GSK-626616

    GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.

  • LDN-212320

    LDN-212320 is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.